Omvoh (mirikizumab-mrkz) FDA-Approved for Moderately to Severely Active Ulcerative Colitis

Author: owner     Published: 1 year ago 0 Replies

In two randomized, double-blind, placebo-controlled clinical trials, the safety and effectiveness of OMVOH were assessed.

The first study (UC-1, NCT03518086) focused on inducing remission, while the second study (UC-2, NCT03524092) aimed at maintaining remission in adults with moderately to severely active ulcerative colitis who did not respond adequately to or could not tolerate corticosteroids, 6-mercaptopurine, azathioprine, biologic therapies (such as TNF blockers, vedolizumab), or tofacitinib.

Bowel Urgency: During both UC-1 and UC-2, the urgency of bowel movements was evaluated using a numerical rating scale (NRS) ranging from 0 to 10.

OMVOH treatment demonstrated a higher proportion of patients with a baseline weekly average NRS score of ≥3 achieving a weekly average score of 0 or 1 at Week 40 compared to the placebo group (39% versus 23%). This favorable outcome was also observed at Week 12.

Endoscopic Assessment:

Endoscopic remission, defined as a Mayo endoscopic subscore of 0, indicated the normalization of the mucosal appearance.

In UC-2 at Week 40, a greater percentage of patients receiving OMVOH achieved endoscopic remission compared to those on placebo (22% versus 14%).

Login to Reply

Money Back Guarantee
We return Money in 24 Hours

Secure online payment
We possess SSL / Secure Certificate

12/7 customer support
Well-trained & Supportive team

PMDC Verified Doctors
Authentic & updated information

emedz.net

Book Online and In-clinic appointments with your doctor. Consult via Video chat and get a prescription. Ask any question in the "Forum" section and get a detailed answer. Discuss your health issues. Advertisers who wish to place ads on emedz.net and reach multiple users can contact here: ads@emedz.net

Connect with us

Copyright @ 2024 - All Rights Reserved Reproduction of material from any pages without permission is strictly prohibited.